clinivation WorldView >
IMTEC- Executing a launch in Japan.
IMTEC’s Japanese agent asserted that the device was a high-risk “Highly Controlled Medical Device”, and required months of additional work (including type testing) and more than $150,000 in additional costs.
Using WorldView as our source of regulatory intelligence, we successfully disputed the agent’s misclassification…Saving months and more than $150,000…”
